Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risks versus benefits: the alteplase experience.

J A Green1

  • 1Cardiovascular Clinical Pharmacology Research Program, Case Western Reserve University, Cleveland, OH.

American Journal of Hospital Pharmacy
|November 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relative sensitivity of plastic scintillator: A comparative analysis with 60Co gamma rays, deuterium-deuterium, and deuterium-tritium neutrons.

The Review of scientific instruments·2024
Same author

Non-adiabatic direct quantum dynamics using force fields: Toward solvation.

The Journal of chemical physics·2024
Same author

Report of a Case of Diphtheria with Rare Complications.

The Southern medical record·2022
Same author

Asymmetric expression of proteins in the granules of the placentomal Binucleate cells in Giraffa camelopardalis†.

Biology of reproduction·2022
Same author

Interspecific and intraspecific foraging differentiation of neighbouring tropical seabirds.

Movement ecology·2021
Same author

Effect of estradiol preceding and progesterone subsequent to ovulation on proportion of postpartum beef cows pregnant.

Animal reproduction science·2021

Alteplase effectively treats acute myocardial infarction (AMI) by dissolving clots, offering improved reperfusion rates compared to older therapies. Pharmacists play a key role in managing this thrombolytic treatment, considering both clinical and economic factors.

Area of Science:

  • Pharmacology
  • Cardiology
  • Biotechnology

Background:

  • Acute myocardial infarction (AMI) is often caused by coronary artery thrombosis.
  • Timely thrombolytic therapy, within 4-24 hours of symptom onset, significantly reduces AMI mortality.
  • Alteplase, a recombinant tissue-type plasminogen activator, offers a targeted approach to clot dissolution.

Purpose of the Study:

  • To describe the characteristics and efficacy of alteplase in treating AMI.
  • To discuss the role of pharmacists in thrombolytic therapy.
  • To compare alteplase with other thrombolytic agents like streptokinase.

Main Methods:

  • Review of alteplase characteristics, including its rapid onset and short half-life.
  • Analysis of alteplase's fibrin affinity and clot-specific action.

Related Experiment Videos

  • Comparison of reperfusion rates and adverse effects with streptokinase.

    • Main Results:

    • Alteplase demonstrates higher reperfusion rates (66-75%) compared to streptokinase (36-76%).
    • Alteplase is generally more effective than streptokinase in initiating reperfusion.
    • The primary adverse effect of alteplase is bleeding; cost is a significant consideration.

    Conclusions:

    • Alteplase is an effective thrombolytic agent for AMI, with improved efficacy over streptokinase.
    • Pharmacists are crucial for developing protocols, monitoring therapy, and educating healthcare professionals and patients.
    • Rational use of thrombolytic agents necessitates careful consideration of clinical benefits and economic consequences.